Objective-To examine the efficacy, dose, and safety profile, including neurophysiological testing of thalidomide used in 59 patients (including 23 with Behcet's disease) to treat severe oral or genital ulceration (OGU). Methods-We identified prospectively subjects (including women ofchildbearing potential) who had persistent OGU over periods lasting one to 40 years and whose active ulceration was not controlled by other therapies. They were treated with thalidomide. Retrospectively, we identified the number of subjects with complete resolution of the ulcers at one and two months of thalidomide therapy, and the dose required to maintain that improvement in those individuals who relapsed after stopping thalidomide. The decrease from the baseline sensory nerve action potential (baseline SNAP) amplitude value (derived from median, radial and sural nerve SNAPs) at which the development ofparaesthesiae was likely to occur was also determined. Results-Complete resolution of the ulcers occurred in 81% of patients within one month ofthalidomide therapy at doses of200 mg/day. No further thalidomide was required by 20% of patients responding and in the remainder improvement was maintained with smaller doses (7-200 mg/ day). Using an approximate 50% decrease from baseline SNAP as an indication to discontinue thalidomide, the incidence of symptomatic neuropathy was 13*5%. No patients with a decrease of less than 42% developed neuropathy, and a further 13 5% were asymptomatic with a decrease in SNAP between 42 and 69%. Other side effects were seen in 44% ofpatients. There were no pregnancies and no requirement for urgent pregnancy testing. Conclusions-Thalidomide provided a usefiu therapeutic option in severe oral and genital ulceration which had not responded to other therapies. The physician must remain vigilant to the continuing danger of axonal neuropathy and teratogenesis at al times during thalidomide therapy.
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NEUROPHYSIOLOGICAL STUDIES
To detect early changes suggestive of axonal neuropathy, SNAP amplitudes of the median, radial, and sural nerves were recorded by standard techniques1012 in a temperature controlled environment by the same observer for all readings in 46 subjects. After baseline readings, studies were repeated every six months or after each 10 g of thalidomide if this occurred earlier.
In the early phase of our thalidomide usage, nerve conduction studies were not performed before treatment in 14 patients. Although all 14 had received less than 7 g before their first study, it became apparent that this could be misleading, as one patient had evidence of axonal neuropathy on his first recording despite only receiving 2-8 g of thalidomide. Subsequently, recordings of SNAP before treatment was begun became mandatory.
In normal subjects the radial nerve has a significantly larger SNAP amplitude than both the median and sural nerves; consequently, when the baseline SNAP value was calculated for each patient, the amplitudes of the three nerves (median, radial, and sural) required equal weighting. For this purpose the SNAP amplitude for each individual nerve at the initial reading was deemed to be 100%, and the three summated. A decrease of approximately 50/O from this baseline total percentage SNAP (baseline SNAP) was prospectively selected as an indication of subclinical neuropathy, and thalidomide was discontinued. SUBSET 
ANALYSIS
Data from a group of 12 patients who had required long term thalidomide treatment necessitating more than four SNAP measurements during their therapy, were analysed further. The amplitudes of the individual nerves and their total SNAPs were calculated and plotted against the cumulative dose of thalidomide, the daily dose of thalidomide, and the duration of thalidomide therapy to determine if the clinical development of peripheral neuropathy could be predicted.
Results

THERAPEUTIC EFFICACY
The efficacy of thalidomide in the whole cohort was such that 81 3% were ulcer free at one month, and 84-7% ulcer free at two months. Of those with idiopathic OGU, 91-6% were ulcer free at one and two months, and in Behcet's disease 73-9% were ulcer free at one month and 82-6% at two months. For the other diagnoses, 72-7% patients were ulcer free within two months. A further two patients improved but never became ulcer free, and seven stopped thalidomide because of side effects before improvement was noted. Of the (table 2) . Four of these eight patients with paraesthesiae had further measurements after stopping thalidomide and these showed an improvement in baseline SNAP, albeit within the 30% variability (table 3) . No further deterioration was noted in the total SNAP amplitude of any patient after thalidomide withdrawal. Six patients reported an improvement in their symptoms, one indicated no change and one died (patient with SLE, tuberculosis and metastatic carcinoma of the breast) before reassessment.
The patient with Behcet's disease and coexistent diabetes mellitus had no demonstrable peripheral neuropathy at any time.
Asymptomatic deterioration in baseline SNAP: putative subclinical neuropathy Eight individuals without paraesthesiae (five with Behcet's disease and three with idiopathic OGU) had a decrease of 42-6-69% from baseline SNAP (table 2) and their thalidomide was discontinued. Subsequently, three of these individuals had further SNAP recordings after stopping therapy; two showed improvement of >30%, and one showed an improvement of less than 30% (table 3) . None of these patients became symptomatic after stopping thalidomide.
Comparison of the 16 patients with clinical and putative subclinical neuropathy with the 34 patients with a decrease of less than 42% showed that the duration of thalidomide treatment was longer in those with 'neuropathy', but there was no difference between the total cumulative doses of the two groups. These data are summarised in table 1. The daily average dose per patient was less in the neuropathic group, reflecting the low doses of thalidomide in those receiving long term therapy, as opposed to the greater dose in those receiving intermittent courses. Within the group of 16 In the literature the reported incidence of lalidomide in peripheral neuropathy in patients taking as Behcet's thalidomide appears to vary between inding severe conditions. In prurigo nodularis it approaches regarded as a 1000%,' contrasting with discoid lupus erythematosus in which the incidence is ry of severe, approximately 28%.17 Leprosy may be a special ilceration, we case, confounded by lepromatous neuropathy; eutic role of however, the incidence does seem genuinely to the resolution be low.2" In idiopathic OGU/Beh9et's disease, % of patients the reported incidence of neuropathy, albeit in The doses of small numbers, lies between 23 and 50%.21 22 ulcers and to Careful monitoring with regular neurophysiodemonstrably logical studies has resulted in lower incidence of symptomatic neuropathy (13-5%) in our 
